We evaluate our preliminary experience using the Cyberknife ® Radiosurgery System in treating benign spinal tumors. A retrospective review of 16 consecutively treated patients, comprising 19 benign spinal tumors, was performed. Histologic types included neurofibroma [11], chordoma [4], hemangioma [2], and meningioma [2]. Three patients had Neurofibromatosis Type 1 (NF1). Only one tumor, recurrent chordoma, had been previously irradiated, and as such not considered in the local failure analysis. Local failure, for the remaining 18 tumors, was based clinically on symptom progression and/or tumor enlargement based on imaging. Indications for spine stereotactic body radiotherapy (SBRT) consisted of either adjuvant to subtotal resection (5/19), primary treatment alone (12/19), boost following external beam radiotherapy (1/19), and salvage following previous radiation (1/19). Median tumor follow-up is 25 months (2-37), and one patient (with NF1) died at 12 months from a stroke. The median total dose, number of fractions, and prescription isodose was 21 Gy (10-30 Gy), 3 fx (1-5 fx), 80% (42-87%). The median tumor volume was 7.6 cc (0.2-274.1 cc). The median V100 (volume V receiving 100% of the prescribed dose) and maximum tumor dose was 95% (77-100%) and 26.7 Gy (15.4-59.7 Gy), respectively.
Introduction
With the development of sophisticated software and image-guided radiotherapy, stereotactic body radiotherapy (SBRT) has emerged as a relatively new technique in the treatment of benign spine tumors located adjacent to or within the spinal cord. In the past, what prevented high dose radiation to these areas was both the inability to conform dose away from the spinal cord/cauda equina and, the difficulty in assuring that dose was deposited precisely where it was intended. liver radiation to the tumor from a cylindrical collimator (1, 2, 26, 42) . This systems major advantage is the unique capacity for intra-fractional near "real-time" imaging based on an internal reference point, allowing for accurate tracking of the target movement with approximately 1 mm spatial accuracy (28, 29, 46) . Should misalignment be detected, it is the robot that adjusts and not the treatment couch, and the intra-fractional imaging frequency is typically set at every 45-60 seconds during treatment for the spine. However, couch adjustments are required for translations beyond 10 mm, or rotational offsets of 1 degree for pitch and roll and 3 degrees for yaw.
Preliminary experience with spine SBRT has been primarily reported for the treatment of spine metastases (18, 19, 44) and already, in North America, there has been report of the devastating late complication of spinal cord myelopathy (15, 22, 33) . Dose to the spinal cord is a major consideration for patients treated with benign disease as they have a long lifeexpectancy and, therefore, time to develop late effects of radiation. As a result, this complication must be weighed against standard microsurgical techniques or conventional radiotherapy, where safety and effectiveness are well documented.
However, for patients in whom neither surgery nor additional or protracted primary radiotherapy are attractive options spine SBRT may be an invaluable treatment alternative. Such circumstances precluding surgery include significant medical co-morbidity, age, and technical considerations (given the frequent need to sacrifice nerve roots or compromise the spinal cord). Surgery may also not be appropriate in patients with multiple benign tumors due to genetic syndromes such as neurofibromatosis.
Benign spine tumors are rare and, as such, there is limited outcome data in patients treated with spine SBRT (3, 5, 13-15, 21, 34, 35, 44) . Furthermore, the optimal total dose, fractionation, margins, dose limitation to organs at risk, and early and late toxicities have yet to be defined. Therefore, the objective of this report is to document preliminary efficacy and toxicity for benign spine tumors treated at the University of California San Francisco (UCSF). We also provide detailed dosimetric data.
Methods and Materials
Sixteen consecutive patients with 19 benign spinal tumors treated at UCSF, from April 2003 to December 2006, were identified in our prospective database. Details were obtained by CHR-approved retrospective chart review. A multidisciplinary team of specialists including radiation oncologists, neurosurgeons, and neuroradiologists evaluated all patients prior to treatment with Cyberknife ® radiosurgery.
Patient characteristics are detailed in Table I. Indications for  spine SBRT are outlined in Table II. One patient with a previously radiated (11 years prior) sacral chordoma was treated with spine SBRT due to recurrence within the radiated field. This tumor had been treated by sub-total resection followed by external beam radiotherapy (45 Gy in 25 fractions) and a proton boost (30 CGE). We exclude this tumor from the local control analysis only given that re-irradiation for chordoma has been shown to result in unlikely local control (10), and the aim in this case was only palliation of pain as opposed to local control.
Three patients with Neurofibromatosis Type 1 (NF1) were treated with spine SBRT for three neurofibroma tumors, respectively. Five patients had intended spine SBRT as adjuvant therapy within three months of surgical resection. In each of these cases, a sub-total surgical resection had been performed with gross residual disease remaining. All major clinical findings for those patients symptomatic at presentation are reported in Table III. The components of the image-guided Cyberknife ® SBRT system have been previously described (1, 26) . However, we will describe briefly our radiosurgery process. All but one patient had 3-5 stainless steel fiducial screws implanted percutaneously into the posterior vertebral elements adjacent to the tumor to be treated. The one patient spared of this procedure was treated after the acquisition in 2006 of the XSight™ skeletal tracking system. This imaging system correlates with osseous anatomical landmarks rather than fiducial markers (28). All patients were treated in the supine position and for those treated for cervical spine tumors a thermoplastic patient-specific mask was used.
Treatment planning first begins upon acquisition of a planning CT scan, and axial images are acquired with a slice thickness of 1.25 mm. Contrast was use for the hemangioblastoma cases. We typically did not use the MRI to fuse to the CT scan as the target was often well visualized, and any potential error in fusion for the spinal cord contour was thought unacceptable. The gross tumor volume (GTV) and organs at risk such as the spinal cord, esophagus, and bowel are contoured by both the neurosurgeon and radiation oncologist. No margin was applied to the GTV. The spinal cord contour consisted of the spinal cord plus intra-thecal contents and, as such, the entire thecal sac was contoured at the level of the tumor and typically 1-2 cm beyond both superiorly and inferiorly. The dose distribution for a neurofibroma case is shown in Figure 1 to highlight these concepts. Similarly, for the cauda equina the entire thecal sac was contoured. The inverse planning computer algorithm (Multiplan ® , Accuray ® , Inc., Sunnyvale) determines the number, direction, and duration of treatment beamlets. Constraints are set to optimize dose conformity and minimize irradiation of critical structures. Typically, we aim to cover the 95% of the PTV by 100% of the prescribed dose (V100=95%), however, this is dependent on the dose to the spinal cord, which is determined on an individual patient basis.
All patients were evaluated following each treatment and every 3-6 months thereafter by the neurosurgeon. Local failure was determine based on imaging documenting tumor growth and/or clinical symptom progression. Pain symptoms were retrospectively assessed and crudely evaluated as either stable, improved, or worsened. Due to the retrospective nature of this study we chose to analyze this endpoint at 6 months post-SBRT; however, one must take into account that no formal pain scoring system was employed and this outcome was based on the physician's assessment. Detailed neurological function follow-up was unreliable given an inconsistent qualitative approach in documentation and, therefore, not formally analyzed. Both acute and late toxicity were retrospectively graded according to the National Cancer Institute Common Toxicity Criteria version 3.0.
The biologic effective dose (BED) was calculated to equate dose and fractionation based on the linear-quadratic model according to:
Where n is the number of fractions, d is the dose per fraction, and α/β refers to the sensitivity of the tissue for which the BED is being referenced to (24). Values of α/β for photon irradiation of the human spinal cord range from 1.5-3 Gy (24). We have chosen a value of 3 to provide comparison to the method used by Gibbs et al. who reported three cases of myelopathy post-SBRT (22). Given that all tumors were benign, the same α/β was chosen for tumor calculation, and the BED tumor calculation was based on the D90 (dose D to 90% of the GTV).
Results
Sixteen patients with 19 spinal tumors were treated, patient characteristics are presented in Table I . The indications for spine SBRT are detailed in Table II . Presenting symptoms are presented in Table III . The median tumor follow-up is 25 months (range, 2-37). All patients had follow-up imaging at time of last follow-up and, no patient was lost to follow-up.
Radiosurgery Dose, Fractionation, and Dosimetric Analysis
The median dose, fractionation, and prescription isodose according to tumor histology is presented in Table IV . We did not impose a restriction on maximum dose within the tumor volume, and this can be appreciated by the large volume receiving at least 115% of the prescribed dose (V115) and maximum tumor point doses (Table IV) . Tumor histology and volume does influence our prescription practice, as for example, the hemangioblastoma and chordoma cases. For hemangioblastoma, as a vascular tumor, we attempt to deliver single fraction radiosurgery based on experience with brain AVMs treated with the Gamma Knife ® . We increased the total dose and fractionation for chordoma given the larger size of these lesions. Doses to the spinal cord and cauda equina are summarized in Table V .
Post-SBRT Outcomes
Excluding the previously irradiated tumor, three local failures occurred at 2, 4, and 36 months post-SBRT (n=18). The median follow up for the remaining tumors was 28.5 months (range 2-37). The Kaplan-Meier estimate of the 12-month freedomfrom-progression is 89% (95% confidence interval=63%-97%). The Kaplan-Meier estimate of 3-year freedom-fromprogression is 71% (95% confidence interval=26%-92%). Only five tumors were followed three years or more.
Two NF1 patients, each with one treated neurofibroma, had progressed despite spine SBRT. In one case, MRI revealed tumor growth and this patient also progressed symptomatically (36 months post-SBRT). For the second, due to symptom progression, this patient was counted as a local failure despite a stable tumor size on MRI (4 months post-SBRT). At the time of last follow-up for these patients, they continue to be observed with the aim of delaying surgical intervention for as long as possible given their multiple spine neurofibromas. However, it is thought that eventually surgery will be required. The total dose, number of fractions, tumor volume, and prescription isodose for these two cases were 21 Gy, 3 fractions, 3.4 cc, and 84%, and 30 Gy, 3 fractions, 26.2 cc, and 72%, respectively. The third case was an intramedullary hemangioblastoma tumor and is discussed separately below.
MRI documented progression occurred in 2/18 tumors (one neurofibroma, one hemangioblastoma), 3/18 had regression (one neurofibroma, one chordoma, one hemangioblastoma), and 13/19 were unchanged. Figure 1 illustrates tumor regression after spine SBRT in one patient treated for a neurofibroma. Pain present before treatment with spine SBRT was improved in 6/13, unchanged in 5/13, and worsened in 2/13 tumors at six months after treatment.
Figure 1:
A 60 year old female with radicular pain was treated for this right sided L3-4 neurofibroma (7.4 cc) with 20 Gy in 2 fractions prescribed to the 84% isodose. The V100=100%, V115=29%, maximum tumor dose 23.9, and BED tumor=87 Gy 3 . The pre-spine SBRT T1 axial post-gadolinium illustrates a 2.2 cm tumor with homogeneous enhancement (1A). The axial CT image used for Cyberknife ® treatment planning shows the GTV in purple color wash and spinal cord contour in green color wash. 1B shows isodose lines relative to the maximum dose of 23.9 Gy. The prescription isodose is the 84% (orange) and, additionally, the 96% and 34% isodose lines are shown which correspond to the V115% and V8Gy. 1C shows an MRI at thirty-six months post-SR indicating response with the hyperintense tumor now measuring 1.8 cm on the axial T1 post-gadolinium image. The heterogeneous enhancement indicates central necrosis.
Figure 2:
A 59 year old male with an intramedullary solid hemangioblastoma was treated with spine SBRT; clinical details are provided in the Results section. 2A is a saggittal T1 post-gadolinium MRI illustrating the enhancing tumor mass to be treated post-subtotal resection (the T2 weighted images indicated minimal associated peri-tumoral edema and not shown).
2B is a saggittal CT image used for spine SR treatment planning with the relevant isodose lines. The GTV (enhancing tumor mass in 2A) is in red color wash, the spinal cord in green color wash, and the isodose line legend is provided. The prescription isodose (P) is the 85% isodose line and relative to the tumor maximum dose of 15.4 Gy. 2C is a saggittal T2 MRI image illustrating a tumor cyst that developed two months post-SBRT just at the inferior edge of the treated GTV. 2D is a saggittal T2 weighted image taken immediately post-gross tumor excision and cystectomy and, 2E is a saggittal T2 weighted MRI image taken 17 months post-SR. Both images show no residual cyst (corresponding T1 post-gadolinium images indicate no residual tumor and are not shown).
The one solid (non-cystic) intramedullary hemangioblastoma patient treated was documented as a local failure due to the appearance of a spontaneous tumor cyst two months after spine SBRT. However, it is unclear if this represents a radiosurgery induced cyst or simply tumor progression. This patient initially presented with left hand weakness and was radiated after subtotal resection for residual gross disease. A saggital MRI view of the patient's pre-SBRT tumor is shown in Figure 2A . This patient's dose distribution is shown in Figure 2B and, in addition to the isodose distribution shown, the conformity index was 1.2. The prescription dose was 13 Gy in 1 fraction prescribed to the 85% isodose. The BED Gy 3 for the target was 69 Gy 3 . The maximum dose, dose to 0.1 cc, 1 cc, and 2 cc of spinal cord was 14.9 Gy, 12.3 Gy, 6.5 Gy, and 4.4 Gy, respectively. The volume of spinal cord receiving ≥ 8 Gy, ≥ 10 Gy, and ≥ 15 Gy was 0.66 cc, 0.3 cc, and 0 cc, respectively. Two months post-SBRT, MRI was performed due to worsening of his pre-existing neurologic deficit and revealed a tumor cyst ( Figure 2C) . After a brief course of steroids, progression to symptomatic myelopathy required an emergency cyst fenestration. Post-op the patient's myelopathic symptoms were completely reversed and the patient's left hand function also improved. The tumor was described intra-operatively as stable and densely adher-ent to the spinal cord and the cyst was successfully fenestrated. Four months later, the patient developed a second local tumor cyst recurrence and both a gross tumor resection and cystectomy were performed. Immediate post-operative T2 weighted MRI image is shown in Figure 2D , illustrating the lack of cyst present and hemorrhage within the tumor cavity.
At the most recent follow-up, the patient has no evidence of recurrent cyst or disease by MRI ( Figure 2E ), and neurologically he has minimal residual left hand dysfunction.
In the case of the previously radiated chordoma, re-irradiation with spine SBRT as a palliative measure resulted in reduction of this patients pain until tumor progression seven months post-SBRT as documented by MRI. No patient experienced worsening neurologic symptoms (for the quadriplegic patient no improvement was noted), and based on MRI no spinal cord/cauda equina radiographic changes have yet been observed.
Toxicity
Cyberknife ® spine SBRT was well tolerated with no acute (within one month post-SR) grade 2-5 toxicity observed. One patient treated for a cervical tumor treated experienced slight nausea (grade 1). Subacutely (1-6 months post-SBRT), it is unclear whether the formation of the tumor cyst described was radiation-induced or part of the natural history of this solid intramedullary hemangioblastoma. No late toxicity has been observed as yet, in particular no myelopathy.
Discussion
Our preliminary data demonstrate that Cyberknife ® radiosurgery for benign spine tumors results in acceptable rates of local control and toxicity. Our pain outcomes are consistent with those reported in the literature, given that most patients remain stable or improve (5, 13-15, 21, 34, 35, 44) . Furthermore, we observed limited toxicity, which also is consistent with available data (5, 13-15, 21, 34, 35, 44) . However, one case of myelopathy has been reported in the benign tumor spine SBRT literature (15). We have yet to observe this com- plication. Based on the patients who failed, specific concerns arise and are the focus of this discussion.
Spine Neurofibromas
These tumors are benign nerve-sheath tumors and tend to invade the nerve root. The transformed neoplastic cells have been shown to be the Schwann cells but these tumors also include nerve cells, axons, fibroblasts, perineural cells, lymphocytes, collagen fibrils, and mast cells. These tumors compose 3.5% of all spinal tumors and are symptomatic only in the minority (38). Although surgery is often performed, pronounced motor deficits have been observed likely due to the infiltrative nature of these tumors into the nerve root and presence of intra-tumoral functioning motor axons (12, 38) . Multiple neurofibromas are often found in patients with NF1.
In our series of 11 neurofibromas treated, the median dose and fractionation was 21 Gy in 3 fractions prescribed to the 80% isodose and, the median BED was 74 Gy 3 . With a dose of 20 Gy in 2 fractions prescribed to the 84% isodose (BED 57 Gy 3 ), Figure 1 demonstrates the efficacy of SBRT in treating these tumors.
Three patients had NF1 and, of the three tumors treated, two suffered progression. The third NF1 patient died from a stroke nine months post-SR with stable disease. In these two patients the BED was high at 69 and 130 Gy 3 , respectively, and both were treated primarily with SBRT (i.e., not post-op).
Dodd et al. report on seven NF1 patients comprising nine tumors treated with spine SBRT (15). He reports the treatment mean dose of 19.8 Gy in an average of 2 fractions (15). In only one patient did tumor enlargement as documented by MRI, however, 50% suffered worsening of symptoms. Therefore, based on our definition of local failure, a significant proportion of these patients failed. Bhatnagar et al. reports on two neurofibroma spine tumors in two patients having NF1, respectively (5). The only neurofibroma patient (n=21) with symptomatic progression, in his series, was in fact a patient with NF1 treated for a cervical spine neurofibroma. This was despite three spine SBRT procedures, and dose totaling 50 Gy to the 80% isodose line. The second NF1 patient was symptomatically stable following treatment with a total dose of 20 Gy to the 80% isodose. Unfortunately, no details as to the number of fractions could be reliably obtained. To our knowledge, the above review represents the sum of all cases for neurofibromas in patients with NF1 treated with spine SBRT in the published literature. Therefore, for neurofibromas treated in NF1 patients, these limited data would support the notion of radiosurgery dose escalation. Another option would be to routinely combine surgical debulking and post-operative radiosurgery (with the aim of sparing the nerve root), or to simply perform surgery alone, since tumor and symptom control with spine SBRT appear sub-optimal for NF1 patients.
Spine Hemangioblastoma
These tumors are benign, sharply circumscribed (often not encapsulated), highly vascular, and completely curable with surgical resection (31). The pattern of growth is highly variable and often associated with peri-tumoral edema or syrinx. Furthermore, common histologic patterns include cyst and microcyst formation that are associated with vascular proliferation.
There is limited experience for spinal hemangioblastma treated with radiation, although a decreased efficacy for radiation has been reported for tumors greater than 3 cm 3 or for those associated with cysts (32). The Stanford group has reported seven intramedullary hemangioblastomas treated with Cyberknife ® spine SBRT (35). Their median total dose, number of fractions, and prescription isodose was 21 Gy, 3 fractions, and 77%, and the median follow-up was 13 months.
No complications and no progression for any of the patients treated were reported. Bhatnagar et al. reported on eight spinal hemangioblastoma patients and, specific details as to the dose and fractionation were not presented (5). However, no toxicity was observed with a median of eight months of follow-up and, the only patient with symptomatic progression in his series was a neurofibroma patient (5).
CNS hemangioblastomas have been reported to hemorrhage spontaneously (23). However, there has been no reported case of spontaneous cyst formation after radiation or surgery (27, 31, 40) . Cyst formation following radiosurgery for AVM, and other benign brain tumors, has been reported (11, 16, 39, 43) . However, this complication tends to take years to develop.
For the one case of a solid intramedullary hemangioblastoma (target volume, 0.3 cc) treated with spine SBRT, the neurosurgeon (D.C) at initial sub-total resection described the tumor as solid, with no associated cyst or syrinx, and bright red in appearance. Pathologic diagnosis confirmed hemangioblastoma, and the SBRT treatment plan for the residual disease is described in Figure 2B . As patients with sub-total resection are at significant risk for tumor progression and symptom recurrence, we treated the patient post-op with spine SBRT (31). The aim in this case was to avoid or delay further surgery. A tumor cyst spontaneously appeared two months post-SBRT, and was confirmed intra-operatively upon cyst fenestration and subsequent tumor/cyst resection ( Figure 2C ). We cannot rule out a sub-acute radiation-induced process/toxicity considering the lack of experience with radiosurgery for intramedullary hemangioblastomas and that it does not fit with the natural history of the disease. This case is presented in Figure 2 .
Based on the above mentioned Stanford series (35), 1/7 hemangioblastoma cases was treated with single fraction radiosurgery and, a total dose of 25 Gy prescribed to the 68% isodose. Our patient was treated with 13 Gy in 1 fraction prescribed to the 80% isodose. Our comparatively low dose may suggest that the cyst, if indeed a radiosurgical complication, is likely not dose related.
Sacral Chordoma
Chordomas arise from notochord remnants and, these rare bone tumors occur solely in the base of skull and axial skeleton (50% originate in the sacrum). Surgery is the main treatment modality and radiation has been shown to be effective as adjuvant therapy (4, 10, 30, 45) . In addition, evidence from the proton literature would suggest that high dose radiation can provide durable local control for unresectable tumors (30).
Mature data for 21 patients treated with fractionated (24-43 fractions) radiation was recently reported by Massachusetts General Hospital (30). They report worse local control in patients treated with surgery and radiation for recurrent disease as opposed to those treated for primary disease. For tumors having been previously radiated, Catton et al. report limited efficacy for re-irradiation as salvage therapy (10). We also found limited palliative benefit (seven months) for our patient, treated for recurrent disease, having failed previous surgery and high dose radiation.
Our results are preliminary given the natural history of this disease where local progression can occur 15 years after treatment (36, 45) . However, in the remaining three chordoma tumors treated we have yet to have a local recurrence (median follow-up 36 months). Imai et al. have reported excellent preliminary (median follow-up 30 months) local control with hypofractionated radiation (25). They report a five year local control rate of 96% using 12 C ions and a dose of 70.4 Gy equivalent in 16 fractions over four weeks.
In the benign spine SBRT literature, Yamada et al. (44) reported on three spine chordoma tumors treated with fractionated stereotactic radiotherapy, and Gerszten et al. reported on two spine chordomas treated with single fraction radiosurgery (20). However, details regarding the prescription, outcome, and follow-up specifically for the chordoma cases were not described.
Spinal Cord Dose Volume Data
Our dosimetric analysis for the cord and cauda equina is presented in Table V . The traditional view based on single fraction radiosurgery, with homogenous radiation, has been a radiation tolerance of 8-10 Gy (41). In terms of 1.8-2 Gy/day fractions, a total dose of 45-50 Gy (17, 37) is accepted as safe. However, as spine radiosurgery results in inhomogeneous dose distributions, a differential dose adsorption within the volume of these neural structures (spinal cord and cauda equina) results in new questions as to the partial volume tolerance of the human spinal cord. Animal data support increasing radiation tolerance for ever smaller volumes of irradiated spinal cord and, as the volume of spinal cord exposed to low dose increases the radiation tolerance decreases for a given small volume of spinal cord receiving a high dose (6-9). Whether human spinal cord tolerance data behave similarly is unknown and, therefore, reporting a spectrum of dose-volume parameters to neural structures irradiated is important.
When considering absolute dose, we demonstrate high doses to the cord considering the maximum point dose and volumes of 0.1 cc and 1 cc of the neural structures. Furthermore, considering volume, we have treated beyond 8-15 Gy to small volumes. Therefore, with a median of 3 fractions we have exceeded the traditional total dose thresholds for these structures with as yet no cases of myelopathy.
Limited cases of spinal cord myelopathy in North America have been reported after spine SBRT. Dodd et al. described a patient with a cervical spine meningioma treated with 24 Gy in 3 fractions who developed posterior column dysfunction eight months post-SR (15). The only dosimetric data reported for this patient's cord dose was the volume of spinal cord receiving >8 Gy being 1.7 cc. We report a median volume of 3.1 cc (range, 0-9.3 cc) receiving ≥ 8 Gy.
Gibbs et al. report three cases of spinal cord myelopathy post-SBRT in patients treated for spine metastases (22). Two of the myelopathy patients had received prior radiation (a spinal cord maximum dose of 25.2 and 40 Gy), and had received a subsequent BED of 46-81 Gy 3 . It was reported that no patient with a BED 3 of ≤ 58 Gy 3 to a volume ≤ 0.15 cc developed myelopathy.
Ryu et al. reported a case of reported myelopathy occurring 13 months post-SBRT (33). This patient had metastatic breast cancer and no prior radiation. Detailed dosimetric data are provided; however, data are based on the percent volume of spinal cord irradiated and not the absolute volumes. The highest cord dose reported for this patient was 14.6 Gy (33). Considering this as a point dose delivered in a single fraction, this dose translates into a BED of 85.7 Gy 3 . Based on the maximum point dose to the spinal cord, we report a median BED of 70 Gy 3 (range 19-94). However, the significance of a point dose (i.e., dose to a singe pixel) alone is questionable and, a spectrum of volume and dose data is likely to be more useful to guide partial volume dose limits.
No recommendations can yet be made to clarify the partial volume tolerance of the spinal cord and risk of myelopathy. Our data represent dose-volume parameters in detail and, to date, these have been safe to both the spinal cord and cauda equina. These doses can be considered a guide only when taken in its entirety (Table V) .
Conclusion
With short follow-up, local control and morbidity following Cyberknife ® spine SBRT for benign spinal tumors appears acceptable. Greater doses for neurofibromas in patients with NF1 may be required to improve local control. Further follow-up is required to determine long-term outcomes.
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